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Introduction China has an estimated 5 million people with tuberculosis (TB). Official policy is
that treatment of all patients is directly observed by health workers; completion
rates are reported to be in excess of 90%, and drugs should be supplied for free.
However, some research suggests there is a gap between the official policies
and practice.
Methods Survey of TB patients in four counties of one municipality; record assessment at
one TB centre; patient and village doctor in-depth interviews.
Results Sixteen per cent (64/401) reported being directly observed every time they took
treatment; less than 5% of TB patients (17/401) were observed by health staff.
Overall, 12.5% (50/401) reported they had not taken any TB drugs in the
previous week, but this varied between the four counties (range 6.2 to 21.7%).
We used survival analysis with medical records at one centre: 74.1% of new
patients collected their drugs for their sixth month of treatment, and 50.3%
attended the final visit at 6 months. Qualitative research indicated direct
observation is neither well understood nor thought to be necessary, and that
patients reported being charged expensive fees for ancillary treatments, such as
liver protection drugs.
Conclusion In China, direct observation is not well implemented and may not be a feasible
policy option. Official completion rates are higher than we found in this study.
The concept of free treatment has become blurred, with charges for additional
tests and drugs, especially liver protection drugs. The government is already
actively tackling these issues, and involvement of managers and others in this
process will be helpful.
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Introduction
The government of China’s 10-year tuberculosis Infectious and
Endemic Disease Control (IEDC) Project introduced the World
Health Organization (WHO) recommended DOTS strategy
in 1991, financed by a loan from the World Bank. The policy
includes directly observed treatment (DOT) (World Health
Organization 2002; World Health Organization 2006), and
China’s national policy is committed exclusively to health
workers directly observing all patients to help improve
tuberculosis (TB) case management (Centre for Disease
Control 2002).
However, performance data have been variable. A national TB
epidemiological survey revealed that only 30–40% of detected
TB patients were under case management by the TB dispensary,
and only 27.3% of all TB patients were estimated to be taking
anti-TB drugs regularly (National Technical Steering Group
of the Epidemiological Sampling Survey for TB 2004). Later
reports from WHO have been more optimistic regarding
DOT coverage: in 2004 it reported that 78% of the Chinese
population had been covered by DOTS by 2002 (World Health
Organization 2004), and were being observed by health workers
when taking their treatments. Performance data collected
through the public health system report cure rates of more
than 90% (Chen et al. 2002; Wang et al. 2007). These widely
varying figures give cause for concern. In addition, there appear
to be problems with implementing the policy of free or
subsidized treatment that is part of the China National TB
Programme (World Bank 1991).
Given the debates around effective policy implementation,
this research was carried out at the instigation of a Municipal
TB programme in collaboration with researchers, to identify
ways that TB health service delivery could be improved. The
research aimed to: a) measure the level of direct observation
by health workers; b) estimate the completion rate from data
within facilities; and c) explore patient and provider views on
factors influencing adherence.
Methods
Study sites
The study municipality is Chongqing, in South West China,
with a population of 30 million, living in a mountainous area,
with a socio-economic profile below average. The Health Bureau
and the municipal TB dispensary implement the TB control
programme. In each of the 40 counties, the programme is
implemented by the county TB dispensary or the County Centre
for Disease Control. In our study, we purposively selected four
counties as representative of the whole of Chongqing, in terms
of socio-economic development, geographic and transportation
condition. This is illustrative of an urban area (JLP), a middle
socio-economic area (RC and LB) and a poor rural area (XS)
(see Table 1). All sites had TB information systems, appropriate
health staff, and were willing to cooperate. Official statistics put
completion rates at about 90% for new patients, in line with
the national average. However, as this was inconsistent with
other resources (National Technical Steering Group of the
Epidemiological Sampling Survey for TB 2004), we therefore
assessed adherence by a patient survey, and made an inde-
pendent estimate from individual patient records at one County
TB Dispensary where records were reasonably well kept and
performance was likely to be optimal.
Patient survey
Smear-positive TB patients who started treatment within
the preceding year (that is, currently on treatment or completed
treatment recently) were the target population of this study.
A sample size of 369 was calculated based on a required
precision of 5% around the 95% confidence interval of adhe-
rence rate. The estimated adherence rate used in sample size
calculation is 60%, according to a pilot estimation using medical
records information. As there were approximately 800 patients
meeting the criteria across the four counties, we sampled every
other smear-positive TB patient registered in the preceding year
at each of the county TB dispensaries.
Patients were asked ‘how often did anybody observe you
taking anti-TB drugs?’ and four choices were given: ‘every time,
most times (more than half), rare (less than half), and
none’. The government national guidelines explicitly state that
patients should be observed ‘every time’ (Centre for Disease
Control 2002). Since TB patients were taking medicine every
other day, ‘Interruption of treatment’ was defined as those who
missed their last three doses; or had run out of medicine for
more than a week. ‘Interruption of treatment’ among patients
recently completing treatment was defined as those who
stopped taking drugs 6 days before the end of the standard
KEY MESSAGES
 Direct observation of drug taking by a health worker is national policy for TB control in China. In the study area
described, less than 5% of patients were directly observed, and health workers and patients did not consider the policy
feasible or necessary.
 Records showed that less than 50% of new patients attended follow up at six months, and irregular treatment
and failure to complete treatment was common under the direct observation policy. This will contribute to the risk
of drug-resistant TB developing and to relapse.
 Anti-TB treatment is supposed to be free, but patients were charged high costs for additional tests and drugs, especially
liver protection drugs. This may represent a considerable financial barrier for TB patients to adhere to treatment.
Despite optimistic estimates from international agencies, current policies, their implementation, and actual TB cure and
completion rates in various areas of China need to be reviewed.
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course, or who had run out of medicine for more than a week
before the end of the standard course. This method provides
a measure, at one point in time, of a patient’s self-reported
recent drug-taking history.
We trained and carefully supervised four postgraduate
students to interview patients. Patients on treatment or recently
completed were identified at each TB dispensary from the
registration book. Most interviews with TB patients were
conducted in their homes; for those patients living far away,
notice was sent out and they were interviewed at the nearest
township health centre. Community health workers and local
health staff were not present during the interview. When a
patient could not be found, we tried to identify and interview
another patient in the village meeting the same criteria. Each
evening, research supervisors checked the completed question-
naires and interviewed the interviewers to make sure all
the items in the questionnaire were correctly understood and
filled in. The data were double entered by two postgraduate
students using Epi Data 2.1. After validation, the data were
analysed using SAS 8.2. Two key indicators (direct observation
and interruption of treatment) were defined and analysed.
Univariate analysis was applied to find out the influencing
factors.
Records analysis at JLP
Monthly summaries of attendance and completion were
recognized as being inaccurate. Therefore, we went to the
original patient records and monitored completion over an
8 month period (January to August of 2004) at the county TB
dispensary, which included both patients who had completed
their treatment and those currently on treatment. We collected
medical records of both new and re-treatment patients. New
patients were defined as patients who had never had treatment
for TB, or who had taken anti-TB drugs for less than 1 month.
Re-treatment patients were those previously treated for TB
whose treatment failed, who defaulted, or who relapsed.
The collection and recording of these data was supervised by
the principal investigator.
We applied survival analysis (Kaplan-Meier method) to
estimate the completion rate. In the analysis, ‘event’ was
defined as patients who withdrew from the standardized short
course chemotherapy because of death, treatment failure,
default or transferring out. ‘Survival time’ was the time interval
from the start of treatment to the ‘event’ of withdrawal.
The unit of ‘survival time’ was by month, as patients were
expected to attend clinics monthly. Patients attending the
clinic on the fifth month, where they would collect their
drugs for their last month of treatment, were considered as
‘treatment completed’. We also calculated the percentage
attending for the final visit at 6 months when cure would
normally be assessed.
In-depth interviews
We interviewed TB patients (33) and village doctors (11) from
all four counties. In each county, we purposefully selected
patients from the county TB register to capture a range of
experiences and views, considering age, gender and including
both new and re-treatment patients.
All participants who were asked to participate agreed to
be interviewed. Village doctors (eight male, three female)
were recruited and interviewed. Standard topic guides were
used to ensure relevant areas were covered during interviews,
including patient and doctor’s opinions about: DOT implemen-
tation, adherence to treatment, cost of TB treatment and
patient management. Interviews were conducted in Chinese
Mandarin, lasted between 30–50 minutes and were tape-
recorded with participants’ informed consent. Interviews were
conducted in participant’s homes or at the nearest township
health centre.
The Framework approach was applied to analyse qualitative
data from in-depth interviews (Richie and Lewis 2003), and
MAXqda software was employed to manage, code and retrieve
data. Tape recordings were transcribed verbatim in Chinese
characters. Two bilingual (Mandarin/English speaking) team
members read through the transcriptions and listed recurring
viewpoints relevant to the areas of questioning and common
themes emerging from the data; this formed the basis of
the thematic framework. Transcriptions were imported into
MAXqda (in Chinese characters) and a coding system set up
based on the thematic framework. Code labels were in English
as MAXqda does not support Chinese labelling. One author
applied the coding system to all interviews.
A bilingual and a non-Mandarin speaking researcher exam-
ined the frequency of coded segments, and combined codes into
Table 1 Characteristics of study counties
County Population
GNP per capita
(Yuan) Terrain
Sputum-positive
TB patients
registered 2004 TB programme status
Cure rate, 2004
routine statisticsy
New Re-treatment
JLP* 799 000 19 426 Urban, hilly 280 Additional Municipal dispensary TB
control programme
91.6 76.7
RC 813 000 5110 Rural, hilly 455 Country authorities have actively
encouraged village doctors to
contribute to TB control
97.1 95.2
LB 517 000 6900 Rural, mountainous 572 Part of Global Fund TB Control
Project 2004
94.2 90.0
XS 605 900 3120 Remote, mountainous 391 Part of Global Fund TB Control
Project 2004
95.0 90.0
*County where we analysed records for actual completion rates in 2004.
yData Source: Routine statistics from Municipal TB Dispensary.
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larger categories, to form six main themes. Coded segments
relevant to each theme were translated into English and
summarized in a chart. This enabled English and bilingual
researchers to look across the data of all cases and explore
differences between sub-groups (patients and doctors, male and
female, new and re-treatment patients, and across counties).
The dimensions of each main theme and differences between
subgroups are described in the results section; illustrative
verbatim quotes for each theme appear in Boxes 1 to 6 in
the Appendix in both Chinese mandarin and English. Of the
patients interviewed, 19 were men, 14 were women of a wide
variety of ages; 23 were new patients; 10 were re-treatment
patients; 8 lived in the city, 11 in a rural hilly area, 6 in a rural
mountainous area, and 8 in a very remote area.
Ethics and funding
Ethical approval was obtained from Chongqing Medical
University. The study was funded by the Ministry of Health
and the Department for International Development UK. The
funding bodies had no involvement with the study design,
analysis or interpretation of the results.
Results
Patient survey
Four hundred and five patients were interviewed
(four excluded because of starting treatment more than
1 year ago). One-third of new patients were treated for
longer than the standard treatment of 6 months. One-fifth of
re-treatment patients (19/90) were treated for longer than the
standard of 8 months (Table A1 in Appendix). In younger age
groups, there were similar numbers of men and women,
but men predominated in the older groups (Table A2).
Only 16% (64/401) of patients reported that they were directly
observed every time they took their drugs (95% CI: 12.4% to
19.6%); 72% reported that they had never been observed
(Table 2). Less than 5% (17/401) were directly observed by
a health worker, and 15 of these patients were from one
particular county where authorities had actively encouraged
village doctors to contribute to TB control (RC county).
The remaining 11% were observed by family members.
Analysis by gender, age group and basic knowledge about TB
showed no association.
At the time of interview, 12.5% (95% CI: 9.2% to 15.7%) of
patients reported ‘interrupted treatment’ by our definition
(missed last three doses, or run out of medicines for more
than a week). This varied considerably by county from 6.2% at
JLP to over 20% in XS (Table 3).
Interruption of treatment was similar in patients who
reported being directly observed and those who did not report
being observed. Interruption was more common in men, and in
people who stated they believed that TB drugs could be stopped
after TB symptoms disappeared (Table 3).
Completion
Table 4 gives the results from the Kaplan Meier analysis from
study site JLP. Of the 151 patients, 1 died (after 1 month), 2
transferred out (missed 2 month appointment), and 2 were
identified as treatment failure (at 3 and 4 months). In this
group, the most optimistic completion estimate is those
attending the clinic 5 months into the treatment, when, for
new patients, their last 1 month of drugs is dispensed. For new
patients, this was 74.1% with 50.3% attending at 6 months,
when a sputum check was normal practice. There were fewer
patients classed as re-treatment, where standard treatment
is meant to be 8 months of treatment: 64.5% attended the
5 month visit, and 42.9% attended at 6 months.
Table 2 Patients reporting on direct observation for TB treatment
n %
Directly observed every time* 64 16.0
Directly observed sometimes 48 11.9
Never directly observed 289 72.1
Total 401 100.0
*Ministry of Health policy at the time of survey.
Table 3 Self-reported interrupted adherence and potential influencing
factors
Possible factors
Interrupted
adherence*
% (n/N) 2 P value
Study site
JLP 6.2% (7/113) 12.14 0.01
RC 13.8% (13/94)
LB 9.8% (10/102)
XS 21.7% (20/92)
Direct observation
Observed
every time
12.5% (8/64) 0.00 0.99
Observed
sometimes
or never
12.5% (42/337)
Gender
Male 15.1% (41/271) 5.42 0.02
Female 6.9% (9/130)
Belief: can TB drugs be stopped after TB symptoms have gone?
Yes 29.3% (34/116) 42.42 <0.01
No 5.6% (16/285)
*Missed drugs for >1 week (last three doses) or ran out of drugs for more
than a week.
Table 4 Adherence for smear-positive TB patients in one County TB
Dispensary (n¼ 151) derived from Kaplan Meier analysis
Patient attendance at follow up
n
At
1 mo
At
2 mo
At
3 mo
At
4 mo
At
5 mo
At
6 mo
New cases 131 95.6 85.5 82.7 79.1 74.1 50.3
Re-treatment
cases
20 84.2 73.7 73.7 64.5 64.5 42.9
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Qualitative findings
Six main themes arose through the analysis using the Frame-
work approach. They represent factors that may influence DOT
implementation and adherence.
1) Most TB patients are responsible themselves for taking
their drugs
Most TB patients said that they took drugs on their own at
home and knew nothing about the records of drug taking
(see Box 1 in Appendix). Some reported that they lived very
close to the village doctor but did not have any supervision of
drug taking. Some even felt surprised when hearing the term
‘direct observation’. None of the village doctors interviewed
mentioned that they directly observed each dose taken by TB
patients. Most of them said that they provided intermittent
home visits and/or telephone calls to remind patients of taking
drugs. Some also acknowledged that they never manage TB
patients in the way of DOT. Village doctors in XS County said
that they had neither heard about it before nor were they
required to conduct it (Box 1).
2) Patients and village doctors regard direct observation
as unnecessary
Many patients reported it was unnecessary to be directly
observed by a doctor. They felt they were able to remember
to take the medicine by themselves; some said they were
motivated to take their drugs because they wanted to be cured
and recover. A few patients regarded supervision as a ‘bother’
to the doctors and a waste of their time. During interviews,
most village doctors said that, with constraints of limited time,
long distance and lack of incentives, it was unrealistic and
unnecessary for them to conduct DOT (Box 2).
3) Most new patients comply with treatment
The majority of new patients interviewed said that they never
forgot to take drugs during the treatment (see Box 3). Village
doctors believed that most TB patients could keep taking drugs,
because they wanted to be cured as early as possible. However,
a minority of doctors gave us examples of patients who had
stopped treatment for various reasons, such as drug side-effects
and financial difficulty.
4) Most patients report they are charged expensive fees
for treatment
Most patients said that they had to pay for TB treatment.
Among them, only a few could differentiate free (anti-TB
drugs) and charged drugs (liver protection drugs) (see Box 4).
Patients complained that it cost them tens to hundreds of Yuan
to buy ‘additional’ drugs and examinations relating to their
treatment; many reported having to borrow money to afford
treatment. The cost of treatment varied between the counties;
patients in RC county described a higher cost for drugs, on
average 200–300 Yuan per month (£13–£20 per month).
The high cost of treatment was also one of the main reasons
mentioned by patients who interrupted drug taking. Village
doctors reported that patients complained to them about the
high cost of treatment, and that they cannot afford examina-
tions and additional drugs.
5) Stigma exists in communities
Many patients described being treated differently by people in
their immediate communities after getting TB. They suggested
neighbours or friends did not like to talk with them, or kept
a certain distance while talking with them for fear of infection
(see Box 5). TB patients tended to conceal their disease from
others for fear of being isolated. Some described being treated
differently by family members. Village doctors also reported
that community residents did not like to get close to TB
patients, because they were afraid of being infected.
6) Village doctors report incentives are less important than
responsibility
Village doctors are supposed to receive 60 Yuan (£4) through
the World Bank/DFID-assisted TB programme for managing
one TB patient for 6 months, but the level of financial support
and implementation of incentive payments varies by county;
one village doctor from RC county said he had never heard
about the incentive payment. Most village doctors interviewed
suggested that even without this money, it was their responsi-
bility to manage TB patients (see Box 6). Some village doctors
also expressed that fixed financial support would help them
to manage patients effectively, since they currently do not
receive any salary from the government, and have to earn their
own living through fees for service.
Discussion
The study results show that health worker direct observation
of TB treatment was low. At county level, between 6.2 to 21.7%
of patients had run out of drugs, or not taken any in the
previous week; and actual completion rates in one county
studied were lower than reported in national statistics.
We paid careful attention to quality. In the questionnaire,
we minimized respondent bias by using carefully trained inde-
pendent interviewers; in the medical record data for survival
analysis, the principal investigator monitored data collection;
and for the qualitative interviews, we paid careful attention to
content and analysis by applying the Framework approach
rigorously to the Chinese narrative. The main constraint of this
study relates to the extent to which it reflects adherence in
other areas of China, as it was carried out in a limited number
of counties. However, there is no reason to believe the study
site has any worse performance than other provinces in China,
and there is a need for more extensive careful recording of true
adherence. In the patient survey, our replacement strategy
would tend to make adherence seem better than it actually
was; nevertheless, it was still low.
The national guideline is that all smear-positive TB patients
should be directly observed for treatment by community health
providers or family members. WHO reported high levels
of direct observation (World Health Organization 2004) and
others have reported good completion rates (Chen et al. 2002;
Wang et al. 2007). Our study showed only 16% of TB patients
were directly observed when taking anti-TB drugs. Whilst the
China reporting system does not actually record whether
patients are directly observed during treatment, nevertheless
the stated national policy is for direct observation.
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We decided to be cautious in our interpretation of the ques-
tion about direct observation by family members. The reason
for this is that we were not clear whether respondents simply
meant that family members happened to be in the room when
they were taking treatment. The concept of direct observation
by another person, including family members, was really quite
unfamiliar, and we did not check whether ‘observation’ actually
also included active participation of the family member in the
whole process. If they are to take on more of a monitoring role,
it is likely that training and instructions will be required.
Health staff did not view the policy as practical or feasible.
Most village doctors are now private practitioners, have no
government salary and make a living through fees for services.
Implementing direct observation is a time-consuming job.
Though the World Bank/DFID-assisted TB control programme
provides 60 Yuan to a village doctor for managing one TB
patient, this money is not always available; if it were available,
60 Yuan is simply not enough payment for the inputs that are
required. This is probably the explanation for some village
doctors reporting that incentives were less important than
responsibility.
The official completion rate in the county we studied was
91.6%, yet our analysis of records, which was in part pros-
pective, indicated the most optimistic completion rate proxy for
new cases was 74.1% (percentage of new patients starting
treatment who visit on month 5 for their last month’s treat-
ment), with only 50.3% attending the final visit at 6 months.
These completion data are from the best performing centre
(JLP) among the four centres, since JLP is one urban district of
Chongqing city and its TB control programme is managed
by a provincial-level facility, while the other three are all in
rural areas and managed by county-level TB dispensaries.
Performance at other centres is likely to be worse, and certainly
self-reported adherence rates at the other centres were much
lower. Thus it is probable that true adherence is considerably
lower at the other centres, and these patients are important
as they are at risk of relapse.
Whether these management issues we identified around
routine statistics are common in other counties in the country
was not the brief of our study, but certainly the findings
indicate some very careful audit and checking is required before
being confident about the apparent high level of performance
of the national TB programme. We would argue that there is
a need for accurate information at all levels in order for staff
to take remedial action: in the county, to follow up individual
patients; in the province, to identify poorly performing counties;
nationally, to help poorly performing provinces; and overall,
to identify areas that are doing well to explore reasons for best
practice.
In addition, the survey of reported patient adherence
suggested irregular treatment was common, with patients
frequently missing doses. This will contribute to the risk of
drug-resistant TB developing.
The interviews with patients and health staff indicated that
far from being free, patients were charged high costs for the
diagnosis and treatment. This appears to be for additional tests
and drugs, especially liver protection drugs, which are widely
recommended by the doctors and appear to be a way of
generating income from patients. These findings are consistent
with other research around charging (Garner and Ziganshina
2005; Xu et al. 2006), and suggest that there may be consi-
derable financial barriers to starting and continuing treatment.
These problems are mainly rooted within the malfunction-
ing health system. Along with the market-oriented economic
reform, government funds for public health facilities
are limited. Now these services rely heavily on service
charges, encouraging public health facilities to supply
revenue-generating services. This is probably why patients
always receive liver protection drugs and prolonged treatment
(Meng et al. 2004). In such circumstances, village doctors, most
of whom receive no salary from government, have no incentive
to take responsibility for DOT.
With the collapse of the programme of rural health insurance
(Feng et al. 1997), it costs the rural poor a lot of money
for health care, even if the health services are supposed to be
‘free’ (Meng et al. 2004). This will contribute extensively
to TB patients’ interruptions and non-adherence to treatment.
The next step is to verify whether the situation found in
these selected counties is similar elsewhere in the country.
Strategic options include both specific approaches to detect and
promptly respond to defaulters (Garner and Ziganshina 2005),
or to involve families (Newell et al. 2006). If family members
are to play the role of direct observation, they need more
appropriate training and supervision. However, the gains with
these approaches are likely to be minimal as there is a broader,
underlying problem. To tackle the systems issues, key measures
need to be taken to improve the whole health system perfor-
mance. It could benefit from further investment from govern-
ment subsidy to assist health facilities and health staff at
county, township and village levels in delivering treatments
that have significant externalities. Improving and expanding
the pilot rural health insurance schemes will also provide more
financial protection to the poor rural population in seeking
appropriate TB health services.
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Appendix
Table A1 The length of treatment patients had already received at the
time of interview
Type of patients
Month New n (%) Re-treatment n (%) Total n (%)
1-6 251 (64.6) 51 (56.6) 302 (62.8)
7-8 83 (26.7) 20 (22.2) 103 (25.7)
9-10 24 (7.7) 17 (18.9) 41 (10.2)
11-12 3 (1.0) 2 (2.2) 5 (1.2)
Total 311 (100.0) 90 (100.0) 401 (100.0)
Table A2 Age and gender of TB patients
Gender
Age (years) Male n (%) Female n (%) Total
0-34 57 (49.1) 59 (50.9) 116
35-54 111 (69.4) 49 (30.6) 160
55þ 103 (82.4) 22 (17.6) 125
Total 271 (67.6) 130 (32.4) 401
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Box 1 Mostly TB patients are responsible themselves for taking their drugs
(11) Female, new patient, XS county:
Q: Did anybody supervise you while you were taking drugs? Q:
A: No, I always took drugs myself. Because I am an adult, not a child. A:
(19) Male, retreated patient, JLP county:
Q: Did any doctor supervise you while you were taking drugs? Q:
A: No doctor witnessed me, I take it myself. A:
Q: Did you take every dose? Q:
A: Yes, the doctor gave me a table, there is a cross and after I take the
drugs I marked it on the table.
A:
Q: Even in the hospital, no doctor supervised you? Q:
A: The patient should have self-awareness to take the drug; otherwise he
cannot be cured.
A:
(28) Male, new patient, LB county:
Q: Did any doctor in county TB centre visit you during your course of treatment? Q:
A: No, no doctor witnessed me. A:
Q: Did they tell you that you should be witnessed by a doctor when you
are taking drugs?
Q:
A: No, who is concerned about you? A:
Q: How about the village doctor, did he visit you? Q:
A: Never. A:
Q: How far is it from his house to your house? Q:
A: Not very far, just several paces, at most 2 minutes. A:
(23) Male, new patient, RC county:
Q: Did anybody supervise you while you are taking drugs? Q:
A: No, no doctor supervised me. There is a table on the drug box; I just
follow that instruction.
A:
Q: Did you have a record for drug taking? [interviewer explained
the table for recording drug taking]
Q:
A: No. A:
Q: Did you know about this record? Q:
A: No. A:
(15) Male, new patient, JLP county:
Q: Did anybody supervise you while you were taking drugs? Q:
A: Whom do I need to witness me? My family knows, they saw me take
drugs.
A:
Continued.
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Qualitative data
Box 1 Continued
(8) Village doctor, older male, LB county:
Q: How do you manage TB patients? Q:
A: Generally I ask him to live separately, (tell him) how to take drugs,
suggest he sterilizes utensils such as bowls, chopsticks, beddings, etc
A:
Q: Did you ever witness him to take drugs? A:
A: In terms of taking drugs, tell you the truth, I seldom, or I never
witness him. I just explained it to him that the drug must be taken
in the morning, before breakfast - because he lives far away.
A:
(1) Village doctor, younger male, XS county:
Q: Have you ever heard of patients being directly managed by village doctors? Q:
A: I have never heard about that. A:
Generally speaking, patients take drugs on their own; sometimes
township doctor visits them. If they can’t find patients, I will help
them. It’s the township doctor’s responsibility, we never do that.
Q: How long will it take you to visit patients? Q:
A: It takes me about 10 minutes and another is 30 minutes respectively
to access my patients.
A:
*Number in brackets is the unique identifier for each interview.
Box 2 Patients and village doctors regard direct observation as unnecessary
(33) Female, retreated patient, XS county:
Q: Do you think it’s necessary for the barefoot doctor [village doctor] to supervise
you when you take drugs?
Q:
A: It’s not necessary for the doctor to supervise me, I am strong-minded,
no matter how hard it is, I will keep on taking drugs.
A:
(23) Male, new patient, RC county:
Q: Do you want anyone to supervise you to take drugs? Q:
A: No, I don’t want anyone. A:
Q: Why? Q:
A: Because there are instructions on the drug box, I can supervise
myself. I don’t think it is necessary.
A:
(6) Female, new patient, RC county:
It’s not necessary. I have self-consciousness; I don’t want to waste their time, they
are so busy. I should be responsible to myself, because I want to recover.
(32) Male, retreated patient, RC county:
Q: Do you think it’s necessary for the village doctor to supervise you to take
drugs?
Q:
Continued.
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Box 2 Continued
A: I don’t think it’s necessary to be supervised by the doctor while taking drugs.
Because of my poor economic situation, I really want to be cured as soon as
possible, so I remember to take every dose. Even if I forget to take drugs before
breakfast I will take it after that. No matter how many pills, I can take them.
A:
(9) Female, new patient, LB county:
I don’t think it’s necessary. I want to be cured as early as possible, so I always
take drugs on time.
(5) Village doctor, older male, JLP county:
Q: Do you think it’s necessary for village doctor to witness patients taking drugs? Q:
A: I think it’s unnecessary. They are patients, they must take drugs. As
long as the doctors explain clearly to them, they will take drugs
without any supervision. Nowadays rural people also value their
lives, and always follow doctors’ suggestions. As long as we explain
clearly, he will take drugs even if doctors don’t visit him.
A:
(8) Village doctor, older male, LB county:
According to the national level TB control guideline I should supervise patients.
However, I cannot meet it because of time and distance constraints.
A:
(10) Village doctor, younger male, LB county:
Q: Have you every heard that TB patients should take drugs with doctor’s
witnessing?
Q:
A: Yes. A:
Q: Do you think it’s feasible or not? Q:
A: I think It’s not feasible. A:
Q: Why? Q:
A: Because it’s impossible for us to spend all the time on one patient,
we just often visit him. It is impossible for us to take care of one
patient all the time.
A:
Box 3 Most new patients comply with treatment
(26) Male, new patient, RC county:
I want to be cured, how can I forget to take drugs? No, I won’t.
(5) Female, new patient, RC county:
Q: If the doctor doesn’t come to supervise you will you take drugs? Q:
A: Yes, I will take drugs because it’s good for my health. A;
(27) Male, new patient, LB county:
I never stop taking drugs.
Now I have finished the 6-month treatment, however, I think if I take
drugs for 1–2 more months, the treatment outcome will be better.
(17) Male, new patient, LB county:
Now I feel better, but I won’t stop treatment unless the doctor asks me to stop.
Continued.
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Box 3 Continued
(31) Male, retreated patient, XS county:
Q: Will you continue your treatment? Q:
A: I have no money. If my daughter sends money back [daughter is a
migrant worker], I will continue to take drugs; otherwise I won’t
take it any more.
A:
(10) Female, retreated patient, LB county:
I took drugs for 2 months and stopped for another 2 months, and then I started
the treatment again. If I have money I will take drugs, if not I will delay going
to buy drugs until I can’t bear it anymore.
After the symptoms disappear, I will stop treatment.
(8) Village doctor, older male, LB county:
The patient wants to be cured, so he would like to take drugs, it’s not necessary
for us to worry about them.
(3) Village doctor, younger female, RC county:
After I told him how to take the drugs, he also paid attention to drug taking and
wants to be cured.
Box 4 Most patients report they are charged expensive fees for treatment
(1) Male, new patient, XS county:
Totally I spent 205 Yuan for 2 months’ treatment, among which, 28 Yuan for
transportation, and the rest is for drugs.
I don’t know some drugs, but I know I paid for Jiuweipian [vitamin
supplements].
(24) Male new patient, RC county:
It’s very difficult. I have to pay 200-300 Yuan each month for Jiehewan [TB
drugs], liver drugs, and drugs to protect stomach.
(16) Male, retreated patient, JLP county:
Although the anti-TB drug is free, I have paid much money for other things.
For example, I paid about 180 Yuan for Huganpian [liver drugs] in the first
month.
(20) Male, retreated patient, JLP county:
I collect free drugs these months, however I still spent more than 400 Yuan. 150
Yuan for 2 examinations, I paid more than 400 Yuan for ‘free treatment’.
(6) Female, new patient, RC county:
Among the drugs for which I paid 380 Yuan, TB drugs only account for very
small part.
I can’t afford those bandit drugs, for which I paid 500-600 Yuan every
time.
(28) Male new patient, LB county:
In the propaganda material it [TB drugs] is said to be free, so I think Jiganpian
[liver drugs] should also be free.
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Box 5 Stigma exists in communities
(26) Male, new patient, RC county:
Now when I meet neighbours, we just say hello to each other, then they
go away.
Before I got TB, we always sit down and chat for a while.
(22) Male, new patient, RC county:
From their words, now I think everybody has a poor impression of me.
They are afraid of being infected by me.
(14) Female, new patient, XS county:
My neighbours knew that I had a disease, but they didn’t know it was
TB.
After knowing my disease and that I can’t do any agriculture
work any more, who want to visit me?
(2) Female, new patient, JLP county:
After they (friends and relatives) knew my disease, they always keep a
certain distance while talking with me.
(25) Male, new patient, RC county:
To me, my friends and neighbours still treat me same as before.
(16) Male, retreated patient, JLP county:
Q: What influence does TB have on your life or work? Q:
A: I didn’t tell anyone about my disease. A:
Q: You think it will impact on you? Q:
A: Definitely, there must be some influences. For example, if I
ask them to play cards nobody will come. Who would like to
come? After all, it’s an infectious disease.
A:
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Box 6 Village doctors report incentives are less important than responsibility
(10) Village doctor, younger male, LB county:
It’s not the business of money. I am a village doctor, even if no money
[management fee], I still need to do it [manage TB patients]. Money is not the
most important issue; the village doctor should have his/her responsibility.
(7) Village doctor, male, RC county:
Even if no money [management fee], I still have to do that job.
It’s not a big loss without the money (60 Yuan), nor a big help with it.
It’s my responsibility, I should do it. To be a village doctor you must
sacrifice something.
(5) Village doctor, older male, JLP county:
Even without money, I still need to do. Just like in the SARS pandemic or
cholera pandemic, we didn’t get even a coin.
(4) Village doctor, younger female, RC county:
I know I can get money for managing patients. I should manage him no matter
whether I can get money, since we live close to each other; we live in the same
village.
(9) Village doctor, younger male, LB county:
If we have certain economic resources we can concentrate on the job. However,
now we have to make money for a living.
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